Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans

Xenobiotica

Volumn 45, Issue 2, 2015, Pages 139-149

  Reyes, Maribel ^a   Hoch, Matthias ^a   Brossard, Patrick ^a   Wagner Redeker, Winfried ^b   Miraval, Tommaso ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Swiss BioAnalytics AG   (Switzerland)

Author keywords

Mass balance; Metabolism; Ponesimod; Sphingosine 1 phosphate receptor

Indexed keywords

ACT 204426; ACT 338375; CARBON 14; CARBON DIOXIDE; DRUG METABOLITE; PONESIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; THIAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CIRCULATION; CLINICAL TRIAL; DIZZINESS; DRUG BLOOD LEVEL; DRUG FECES LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG URINE LEVEL; ELIMINATION HALF-LIFE; EXPIRED AIR; EXPOSURE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID SCINTILLATION COUNTING; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; MORNING DOSAGE; NORMAL HUMAN; RADIOACTIVITY; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; CHEMISTRY; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SCINTILLATION COUNTING;

ADMINISTRATION, ORAL; HUMANS; MALE; MIDDLE AGED; RECEPTORS, LYSOSPHINGOLIPID; SCINTILLATION COUNTING; THIAZOLES;

EID: 84919773619     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.955832     Document Type: Article

References (14)

1. Braley TJ, Segal BM. (2013). B-cell targeting agents in the treatment of multiple sclerosis. Curr Treat Options Neurol 15:259-69.
2. Brossard P, Derendorf H, Xu J, et al. (2013). Phamacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol 76: 888-96.
3. Brossard P, Scherz M, Halabi A, et al. (2014). Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration. J Clin Pharmacol 54:179-88.
4. Bruderer S, Hopfgartner G, Selbering M, et al. (2012). Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica 42:901-10.
5. Cai Y, Flemming C, Yan J. (2012). New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol 9:302-9.
6. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (1996).
7. Guideline for Good Clinical Practice CPMP, E6(R1), Geneva, Switzerland.
8. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). (2009).
9. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals, M3(R2), 5, Geneva, Switzerland.
10. Olsson T, Boster A, Fernandez O, et al. (2014). Oral ponesimod in relapsing remeating multiple sclerosis: a randomized phase II trial. J Neurol Neurosurg Phsychiatry. [Epub ahead of print]. doi: 10.1136/jnnp-2013-307282.
11. Piali L, Froidevaux S, Hass P, et al. (2011). The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte- mediated tissue inflammation. J Pharmacol Exp Ther 337: 574-56.
12. Reyes M, Brossard P, Chassard D, et al. (2014). Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive. Eur J Clin Pharmacol 70: 287-93.
13. Roffey SJ, Obach RS, Gedge JI, Smith DA. (2007). What is the objective of the mass balance study' A retrospective analysis of data in animal and human excretion studies employing radiolabelled drugs. Drug Metab Rev 39:17-43.
14. Vaclavkova A, Chimenti S, Areberger P, et al. (2014). Efficacy, safety, and tolerability of ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. [Epub ahead of print]. doi: 10.1016/S0140-6736(14) 60803-5.